Masimo Corporation $MASI Shares Sold by Allspring Global Investments Holdings LLC

Key Points

• Allspring Global Investments Holdings LLC reduced its stake in Masimo Corporation by 45.4% during the second quarter, selling 17,405 shares and now owning 20,897 shares valued at approximately $3.53 million.
• Insider Director William R. Jellison bought 3,000 shares of Masimo at an average price of $145.98, increasing his ownership by 167.6% and bringing his total to 4,790 shares valued at around $699,244.20.
• Masimo shares are currently rated with an average of "Moderate Buy" from analysts, with price targets ranging from $194.60 to $210.00 amidst varied ratings from institutions.

Allspring Global Investments Holdings LLC lowered its holdings in Masimo Corporation (NASDAQ:MASI - Free Report) by 45.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,897 shares of the medical equipment provider's stock after selling 17,405 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Masimo were worth $3,532,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MASI. Farther Finance Advisors LLC lifted its holdings in Masimo by 128.9% during the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 116 shares in the last quarter. GAMMA Investing LLC increased its position in Masimo by 58.4% during the first quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider's stock worth $123,000 after purchasing an additional 272 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of Masimo by 2.7% during the first quarter. State of Alaska Department of Revenue now owns 5,204 shares of the medical equipment provider's stock valued at $866,000 after acquiring an additional 135 shares during the last quarter. Wealthquest Corp acquired a new stake in shares of Masimo during the first quarter valued at about $352,000. Finally, Perpetual Ltd acquired a new position in shares of Masimo in the first quarter valued at approximately $5,033,000. Institutional investors and hedge funds own 85.96% of the company's stock.

Insider Buying and Selling

In other Masimo news, Director William R. Jellison purchased 3,000 shares of Masimo stock in a transaction that occurred on Monday, August 11th. The stock was purchased at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the transaction, the director directly owned 4,790 shares in the company, valued at $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 16.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on MASI shares. Weiss Ratings restated a "sell (d)" rating on shares of Masimo in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Masimo from a "hold" rating to a "buy" rating in a research note on Tuesday, October 14th. Zacks Research upgraded shares of Masimo from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 3rd. BTIG Research reiterated a "buy" rating and issued a $198.00 price target on shares of Masimo in a research note on Thursday, September 11th. Finally, Piper Sandler lifted their price target on shares of Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Masimo has an average rating of "Moderate Buy" and an average price target of $194.60.

Masimo Stock Up 0.2%

Shares of NASDAQ:MASI opened at $147.01 on Tuesday. The company has a market capitalization of $7.99 billion, a PE ratio of -17.25 and a beta of 1.28. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57. Masimo Corporation has a twelve month low of $133.70 and a twelve month high of $194.88. The firm has a 50 day simple moving average of $145.59 and a 200-day simple moving average of $154.59.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The firm had revenue of $617.00 million during the quarter. On average, equities analysts predict that Masimo Corporation will post 4.1 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.